表紙
市場調查報告書

神經退化性疾病治療藥:機會評估,流行病學預測,市場動態,開發平台分析

Neurodegenerative Diseases - Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analytics H2 2019

出版商 GervanoRA Data Services LLP 商品編碼 917777
出版日期 內容資訊 英文 273 Pages
商品交期: 最快1-2個工作天內
價格
神經退化性疾病治療藥:機會評估,流行病學預測,市場動態,開發平台分析 Neurodegenerative Diseases - Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analytics H2 2019
出版日期: 2019年12月04日內容資訊: 英文 273 Pages
簡介

本報告提供全球神經退化性疾病治療藥市場相關調查分析,現在、未來的機會為焦點,市場價值,專利分析,市場佔有率等相關的系統性資訊。

第1章 簡介

第2章 摘要整理

第3章 疾病概要

  • 調查對象的疾病
    • 阿茲海默症 (AD)
    • 帕金森氏症 (PD)
    • 肌肉萎縮性側索硬化症 (ALS)
    • 多發性硬化症 (MS)
    • 亨丁頓舞蹈症 (HD)
  • 流行病學研究、預測

第4章 市場動態

  • 交易 (M&A,聯盟)
  • 專利分析 (失效,學名藥)

第5章 開發平台分析

  • 開發平台分析:阿茲海默症
  • 開發平台分析:帕金森氏症
  • 開發平台分析:肌肉萎縮性側索硬化症 (ALS)
  • 開發平台分析:多發性硬化症
  • 開發平台分析:亨丁頓舞蹈症
  • 開發平台分析:進行性上眼神經核麻痺症

第6章 核准計劃的預測

  • 調查手法
  • 核准計劃的預測

第7章 機會評估和競爭基準

第8章 現在、未來的競爭情形

  • 新興企業
    • 簡介、SWOT分析
      • SANOFI
      • 田邊三菱製藥株式會社
      • ADAMAS PHARMACEUTICALS, INC
      • BIOGEN INC
      • NOVARTIS INTERNATIONAL AG
  • 現有企業
    • 簡介
      • BIOHAVEN PHARMACEUTICALS INC
      • AXSOME THERAPEUTICS INC
      • AZTHERAPIES INC
      • BRAINSTORM CELL THERAPEUTICS INC
      • MEDICINOVA INC
      • MAPI PHARMA LTD
      • TG THERAPEUTICS
      • AB SCIENCE
      • INTEC PHARMA
      • CORTEXYME
      • INTRA-CELLULAR THERAPIES INC
      • ANAVEX LIFE SCIENCES CORP
      • AGENEBIO INC
      • ALZHEON INC
      • SOM BIOTECH
目錄
Product Code: GERPH632

GervanoRA's pipeline analysis and opportunity assessment report "Neurodegenerative Diseases - Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analytics H2 2019" analyzed and assessed Neurodegenerative Diseases pipeline molecules for the opportunities in the competitive space with a major focus on the Top five indications - Alzheimer's disease (AD), Parkinson's disease (PD), Amyotrophic Lateral Sclerosis (ALS), Huntington's Disease (HD) and Multiple Sclerosis (MS).

The report provides detailed insights about all the pipeline molecules in different stages of development and all the companies which are actively involved in Neurodegenerative diseases (NDD) industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Molecules by Route of Administration, Pipeline Molecules by Geography, Pipeline Molecules by Drug Class, Pipeline Molecules by Mechanism of Action and Pipeline Molecules by Stage of development.

Our comprehensive analysis on the NDD drug pipeline identified more than 600 drug candidates undergoing different stages of development- from Early R&D to Pre-registration stage for the top five indications. Among these, seven are in Pre-registration stage, 44 molecules are in the Phase 3 stage of development, 121 molecules are in Phase 2, 98 molecules are in Phase 1 and a total of 330 molecules are in non clinical stage of development.

The report has covered more than 530 companies worldwide, involved in the development of new therapeutics for the mentioned top five indications. Growth opportunities in the report have been provided by performing a competitive and comparative analysis on the top 15 Emerging companies in the domain and hence deriving the key leader.

GervanoRA's analytics observes more than 200 drug candidates in the Alzheimer's disease drug pipeline, 164 in Parkinson's disease drug pipeline making up the major share among the five indications. A total of 90 drug candidates for Amyotrophic Lateral Sclerosis, 88 drug candidates for Multiple Sclerosis and 59 for Huntington's disease are under development. Brief analytics have also been provided for the companies involved in the development of therapeutics for Progressive Supranuclear Palsy (PSP). More than 15 companies are focusing on the development of drug molecules for PSP.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

  • Unmet needs and Opportunities
  • Epidemiology and Epidemiology forecast till 2025 for the indications- Alzheimer's disease (AD), Parkinson's disease (PD) and Amyotrophic Lateral Sclerosis (ALS)
  • Market Dynamics with Coverage of Deals (Mergers, Acquisitions, Partnering, Collaborations etc.) for all five indications
  • Patent Analysis of Pipeline Molecules
  • Pipeline Analysis and Estimated Pipeline Drug Approval Time lines of Key Late-Stage Drug Candidates
  • Current and Future Competitive Landscape
  • Key Established Company Profiles with SWOT Analysis
  • Emerging Company Profiles with Opportunity Assessments

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. REPORT DESCRIPTION
  • 1.2. METHODOLOGY
  • 1.3. UPCOMING AND OTHER AVAILABLE PIPELINE ANALYSIS REPORTS
  • 1.4. ABOUT US: GERVANORA DATA SERVICES

2. EXECUTIVE SUMMARY

  • 2.1. REPORT SUMMARY
  • 2.2. REPORT MAJOR FINDINGS
    • 2.2.1. DRIVERS
    • 2.2.2. RESTRAINTS
    • 2.2.3. OPPORTUNITIES

3. DISEASE OVERVIEW

  • 3.1. DISEASES COVERED IN THE REPORT
    • 3.1.1. ALZHEIMER'S DISEASE (AD)
    • 3.1.2. PARKINSON'S DISEASE (PD)
    • 3.1.3. AMYOTROPHIC LATERAL SCLEROSIS (ALS)
    • 3.1.4. MULTIPLE SCLEROSIS (MS)
    • 3.1.5. HUNTINGTON'S DISEASE (HD)
  • 3.2. EPIDEMIOLOGY STUDIES AND FORECAST OF THREE MAJOR AFFECTING NEURODEGENERATIVE DISEASES
    • 3.2.1. ALZHEIMER'S DISEASE
      • 3.2.1.1. GLOBAL AND HISTORICAL TRENDS
      • 3.2.1.2. EPIDEMIOLOGY FORECAST
    • 3.2.2. PARKINSON'S DISEASE
      • 3.2.2.1. GLOBAL AND HISTORICAL TRENDS
      • 3.2.2.2. EPIDEMIOLOGY FORECAST
    • 3.2.3. AMYOTROPHIC LATERAL SCLEROSIS (ALS)
      • 3.2.3.1. GLOBAL AND HISTORICAL TRENDS
      • 3.2.3.2. EPIDEMIOLOGY FORECAST

4. MARKET DYNAMICS

  • 4.1. DEALS (MERGERS/ ACQUISITIONS/ COLLABORATIONS)
    • 4.1.1. DEALS ANALYTICS BY DEAL TYPE
    • 4.1.2. DEALS ANALYTICS BY ANNUAL FREQUENCY
    • 4.1.3. DEALS ANALYTICS BY DISEASE AREA
  • 4.2. PATENT ANALYTICS (EXPIRES AND GENERICIZATION)
    • 4.2.1. PATENT ANALYTICS OF PIPELINE DRUGS

5. PIPELINE ANALYTICS OF MAJOR AFFECTING NEURODEGENERATIVE DISEASES

  • 5.1. PIPELINE ANALYTICS - ALZHEIMER'S DISEASE
    • 5.1.1. PIPELINE ANALYTICS BY STAGE OF DEVELOPMENT
      • 5.1.1.1. PHASE 3 MOLECULES
      • 5.1.1.2. PHASE 2 MOLECULES
      • 5.1.1.3. PHASE 1 MOLECULES
      • 5.1.1.4. PRECLINICAL MOLECULES
      • 5.1.1.5. EARLY R&D MOLECULES
    • 5.1.2. PIPELINE ANALYTICS BY GEOGRAPHY
      • 5.1.2.1. UNMET NEEDS AND OPPORTUNITIES
    • 5.1.3. PIPELINE ANALYTICS BY ROUTE OF ADMINISTRATION
      • 5.1.3.1. UNMET NEEDS AND OPPORTUNITIES
    • 5.1.4. PIPELINE ANALYTICS BY DRUG CLASS
      • 5.1.4.1. UNMET NEEDS AND OPPORTUNITIES
    • 5.1.5. PIPELINE ANALYTICS BY MECHANISM OF ACTION
      • 5.1.5.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.2. PIPELINE ANALYTICS - PARKINSON'S DISEASE
    • 5.2.1. PIPELINE ANALYTICS BY STAGE OF DEVELOPMENT
      • 5.2.1.1. PRE-REGISTRATION MOLECULES
      • 5.2.1.2. PHASE 3 MOLECULES
      • 5.2.1.3. PHASE 2 MOLECULES
      • 5.2.1.4. PHASE 1 MOLECULES
      • 5.2.1.5. PRECLINICAL MOLECULES
      • 5.2.1.6. EARLY R&D MOLECULES
    • 5.2.2. PIPELINE ANALYTICS BY GEOGRAPHY
      • 5.2.2.1. UNMET NEEDS AND OPPORTUNITIES
    • 5.2.3. PIPELINE ANALYTICS BY ROUTE OF ADMINISTRATION
      • 5.2.3.1. UNMET NEEDS AND OPPORTUNITIES
    • 5.2.4. PIPELINE ANALYTICS BY DRUG CLASS
      • 5.2.4.1. UNMET NEEDS AND OPPORTUNITIES
    • 5.2.5. PIPELINE ANALYTICS BY MECHANISM OF ACTION
      • 5.2.5.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.3. PIPELINE ANALYTICS - AMYOTROPHIC LATERAL SCLEROSIS
    • 5.3.1. PIPELINE ANALYTICS BY STAGE OF DEVELOPMENT
      • 5.3.1.1. PRE-REGISTRATION MOLECULES
      • 5.3.1.2. PHASE 3 MOLECULES
      • 5.3.1.3. PHASE 2 MOLECULES
      • 5.3.1.4. PHASE 1 MOLECULES
      • 5.3.1.5. PRECLINICAL MOLECULES
      • 5.3.1.6. EARLY R&D MOLECULES
    • 5.3.2. PIPELINE ANALYTICS BY GEOGRAPHY
      • 5.3.2.1. UNMET NEEDS AND OPPORTUNITIES
    • 5.3.3. PIPELINE ANALYTICS BY ROUTE OF ADMINISTRATION
      • 5.3.3.1. UNMET NEEDS AND OPPORTUNITIES
    • 5.3.4. PIPELINE ANALYTICS BY DRUG CLASS
      • 5.3.4.1. UNMET NEEDS AND OPPORTUNITIES
    • 5.3.5. PIPELINE ANALYTICS BY MECHANISM OF ACTION
      • 5.3.5.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.4. PIPELINE ANALYTICS - MULTIPLE SCLEROSIS
    • 5.4.1. PIPELINE ANALYTICS BY STAGE OF DEVELOPMENT
      • 5.4.1.1. PRE-REGISTRATION MOLECULES
      • 5.4.1.2. PHASE 3 MOLECULES
      • 5.4.1.3. PHASE 2 MOLECULES
      • 5.4.1.4. PHASE 1 MOLECULES
      • 5.4.1.5. PRECLINICAL MOLECULES
      • 5.4.1.6. EARLY R&D MOLECULES
    • 5.4.2. PIPELINE ANALYTICS BY ROUTE OF ADMINISTRATION
      • 5.4.2.1. UNMET NEEDS AND OPPORTUNITIES
    • 5.4.3. PIPELINE ANALYTICS BY DRUG CLASS
      • 5.4.3.1. UNMET NEEDS AND OPPORTUNITIES
    • 5.4.4. PIPELINE ANALYTICS BY MECHANISM OF ACTION
      • 5.4.4.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.5. PIPELINE ANALYTICS - HUNTINGTON'S DISEASE
    • 5.5.1. PIPELINE ANALYTICS BY STAGE OF DEVELOPMENT
      • 5.5.1.1. PHASE 3 MOLECULES
      • 5.5.1.2. PHASE 2 MOLECULES
      • 5.5.1.3. PHASE 1 MOLECULES
      • 5.5.1.4. PRECLINICAL MOLECULES
      • 5.5.1.5. EARLY R&D MOLECULES
    • 5.5.2. PIPELINE ANALYTICS BY ROUTE OF ADMINISTRATION
      • 5.5.2.1. UNMET NEEDS AND OPPORTUNITIES
    • 5.5.3. PIPELINE ANALYTICS BY DRUG CLASS
      • 5.5.3.1. UNMET NEEDS AND OPPORTUNITIES
    • 5.5.4. PIPELINE ANALYTICS BY MECHANISM OF ACTION
      • 5.5.4.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.6. PIPELINE ANALYTICS - PROGRESSIVE SUPRANUCLEAR PALSY

6. ESTIMATED APPROVAL TIMELINES

  • 6.1. METHODOLOGY
  • 6.2. ESTIMATED APPROVAL TIMELINES US & EX-US

7. OPPORTUNITY ASSESSMENT AND COMPETITIVE BENCH-MARKING

  • 7.1. EXTERNAL DEPENDENCIES
  • 7.2. PIPELINE PORTFOLIO
  • 7.3. EXPECTED MARKET ENTRIES
  • 7.4. PATENTS AND EXCLUSIVITY
  • 7.5. MARKET DYNAMICS WITH PARTNERING ACTIVITIES
  • 7.6. ACHIEVEMENTS OF SPECIAL REGULATORY ALLOWANCES
  • 7.7. COMPANY DEVELOPMENTS

8. CURRENT AND FUTURE COMPETITIVE LANDSCAPE

  • 8.1. ESTABLISHED COMPANIES
    • 8.1.1. KEY ESTABLISHED COMPANY PROFILES AND SWOT ANALYSIS
      • 8.1.1.1. SANOFI
      • 8.1.1.2. MITSUBISHI TANABE PHARMA CORPORATION
      • 8.1.1.3. ADAMAS PHARMACEUTICALS, INC
      • 8.1.1.4. BIOGEN INC
      • 8.1.1.5. NOVARTIS INTERNATIONAL AG
  • 8.2. EMERGING COMPANIES
    • 8.2.1. KEY EMERGING COMPANY PROFILES
      • 8.2.1.1. BIOHAVEN PHARMACEUTICALS INC
      • 8.2.1.2. AXSOME THERAPEUTICS INC
      • 8.2.1.3. AZTHERAPIES INC
      • 8.2.1.4. BRAINSTORM CELL THERAPEUTICS INC
      • 8.2.1.5. MEDICINOVA INC
      • 8.2.1.6. MAPI PHARMA LTD
      • 8.2.1.7. TG THERAPEUTICS
      • 8.2.1.8. AB SCIENCE
      • 8.2.1.9. INTEC PHARMA
      • 8.2.1.10. CORTEXYME
      • 8.2.1.11. INTRA-CELLULAR THERAPIES INC
      • 8.2.1.12. ANAVEX LIFE SCIENCES CORP
      • 8.2.1.13. AGENEBIO INC
      • 8.2.1.14. ALZHEON INC
      • 8.2.1.15. SOM BIOTECH

LIST OF TABLES

  • TABLE 01: REPORT HIGHLIGHTS IN NUMERICALS
  • TABLE 02: ALZHEIMER'S DISEASE EPIDEMIOLOGY (2018) AND FORECAST (2019-2025) IN MILLION
  • TABLE 03: PARKINSON'S DISEASE EPIDEMIOLOGY (2018) AND FORECAST (2019-2025) IN MILLION
  • TABLE 04: NEURODEGENERATIVE DISEASES MAJOR COLLABORATION DEALS, BY DEAL AMOUNT
  • TABLE 05: NEURODEGENERATIVE DISEASES MAJOR MERGER AND ACQUISITION DEALS
  • TABLE 06: NEURODEGENERATIVE DISEASES MAJOR FINANCING DEALS, BY DEAL AMOUNT
  • TABLE 07: NEURODEGENERATIVE DISEASES MAJOR LICENSING DEALS, BY DEAL AMOUNT
  • TABLE 08: MAJOR DEALS FOR NEURODEGENERATIVE DISEASES (2019)
  • TABLE 09: OVERVIEW OF COMPANY PATENT EXPIRIES
  • TABLE 10: NEURODEGENERATIVE PIPELINE MOLECULES BY STAGE OF DEVELOPMENT AND TOP 5 INDICATIONS
  • TABLE 11: PHASE 3 MOLECULES IN ALZHEIMER'S DISEASE DRUG PIPELINE
  • TABLE 12: PHASE 2 MOLECULES IN ALZHEIMER'S DISEASE DRUG PIPELINE
  • TABLE 13: PHASE 1 MOLECULES IN ALZHEIMER'S DISEASE DRUG PIPELINE
  • TABLE 14: PRECLINICAL MOLECULES IN ALZHEIMER'S DISEASE DRUG PIPELINE
  • TABLE 15: R&D MOLECULES IN ALZHEIMER'S DISEASE DRUG PIPELINE
  • TABLE 16: PIPELINE ANALYTICS BY DRUG CLASS, ALZHEIMER'S DISEASE
  • TABLE 17: PIPELINE ANALYTICS BY MECHANISM OF ACTION, ALZHEIMER'S DISEASE
  • TABLE 18: PRE-REGISTRATION MOLECULES IN PARKINSON'S DISEASE DRUG PIPELINE
  • TABLE 19: PHASE 3 MOLECULES IN PARKINSON'S DISEASE DRUG PIPELINE
  • TABLE 20: PHASE 2 MOLECULES IN PARKINSON'S DISEASE DRUG PIPELINE
  • TABLE 21: PHASE 1 MOLECULES IN PARKINSON'S DISEASE DRUG PIPELINE
  • TABLE 22: PRECLINICAL MOLECULES IN PARKINSON'S DISEASE DRUG PIPELINE
  • TABLE 23: R&D MOLECULES IN PARKINSON'S DISEASE DRUG PIPELINE
  • TABLE 24: PIPELINE ANALYTICS BY DRUG CLASS, PARKINSON'S DISEASE
  • TABLE 25: PIPELINE ANALYTICS BY MECHANISM OF ACTION, PARKINSON'S DISEASE
  • TABLE 26: PHASE 3 MOLECULES IN AMYOTROPHIC LATERAL SCLEROSIS DRUG PIPELINE
  • TABLE 27: PHASE 2 MOLECULES IN AMYOTROPHIC LATERAL SCLEROSIS DRUG PIPELINE
  • TABLE 28: PHASE 1 MOLECULES IN AMYOTROPHIC LATERAL SCLEROSIS DRUG PIPELINE
  • TABLE 29: PRECLINICAL MOLECULES IN AMYOTROPHIC LATERAL SCLEROSIS DRUG PIPELINE
  • TABLE 30: EARLY R&D MOLECULES IN AMYOTROPHIC LATERAL SCLEROSIS DRUG PIPELINE
  • TABLE 31: AMYOTROPHIC LATERAL SCLEROSIS PIPELINE ANALYSIS BY ORAL ROA
  • TABLE 32: AMYOTROPHIC LATERAL SCLEROSIS PIPELINE MOLECULES BY INJECTABLE AS ROA
  • TABLE 33: CELL THERAPIES AND GENE THERAPIES UNDER DEVELOPMENT FOR ALS
  • TABLE 34: RECENTLY APPROVED DRUGS FOR MULTIPLE SCLEROSIS
  • TABLE 35: PHASE 3 MOLECULES IN MULTIPLE SCLEROSIS DRUG PIPELINE
  • TABLE 36: PHASE 2 MOLECULES IN MULTIPLE SCLEROSIS DRUG PIPELINE
  • TABLE 37: PHASE 1 MOLECULES IN MULTIPLE SCLEROSIS DRUG PIPELINE
  • TABLE 38: PRECLINICAL MOLECULES IN MULTIPLE SCLEROSIS DRUG PIPELINE
  • TABLE 39: EARLY R&D MOLECULES IN MULTIPLE SCLEROSIS DRUG PIPELINE
  • TABLE 40: ORALLY ADMINISTERED KEY PIPELINE MOLECULES
  • TABLE 41: INTRAVENOUSLY ADMINISTERED KEY PIPELINE MOLECULES
  • TABLE 42: SUBCUTANEOUSLY ADMINISTERED KEY PIPELINE MOLECULES
  • TABLE 43: PHASE 2 MOLECULES IN HUNTINGTON'S DISEASE DRUG PIPELINE
  • TABLE 44: PHASE 1 MOLECULES IN HUNTINGTON'S DISEASE DRUG PIPELINE
  • TABLE 45: PRECLINICAL MOLECULES IN HUNTINGTON'S DISEASE DRUG PIPELINE
  • TABLE 46: EARLY R&D MOLECULES IN HUNTINGTON'S DISEASE DRUG PIPELINE
  • TABLE 47: HUNTINGTON'S DISEASE PIPELINE MOLECULES BY ORAL ROA
  • TABLE 48: HUNTINGTON'S DISEASE PIPELINE MOLECULES BY INJECTABLE ROA
  • TABLE 49: DRUG CLASSES OF HUNTINGTON'S DISEASE PIPELINE DRUG CANDIDATES
  • TABLE 50: PROGRESSIVE SUPRANUCLEAR PALSY DRUG MOLECULES IN PIPELINE
  • TABLE 51: APPROVAL TIMELINES COMPARISON, GERVANORA ESTIMATIONS V/S ACTUAL APPROVAL
  • TABLE 52: ESTIMATED APPROVAL TIMELINE OF KEY PIPELINE DRUGS FOR NEURODEGENERATIVE DISEASES
  • TABLE 53: RANKING OF TOP EMERGING COMPANIES BASED ON REGULATORY ALLOWANCES
  • TABLE 54: REVENUES GAINED THROUGH THE SALE OF MAJOR PRODUCTS IN MILLION $
  • TABLE 55: SANOFI'S OWNED PATENTS COVERING NEURODEGENERATION DISORDERS
  • TABLE 56: SANOFI'S DEVELOPMENT PIPELINE UNDER NEURODEGENERATION
  • TABLE 57: SANOFI'S DEVELOPMENT PIPELINE UNDER INFLAMMATION AND IMMUNOLOGY
  • TABLE 58: SANOFI'S DEVELOPMENT PIPELINE UNDER ONCOLOGY
  • TABLE 59: SANOFI'S DEVELOPMENT PIPELINE UNDER RARE DISEASES
  • TABLE 60: SANOFI'S DEVELOPMENT PIPELINE UNDER RARE BLOOD DISORDERS
  • TABLE 61: SANOFI'S DEVELOPMENT PIPELINE UNDER VACCINES
  • TABLE 62: SANOFI'S RESEARCH AND DEVELOPMENT ACTIVITIES
  • TABLE 63: SANOFI'S RECENT DEVELOPMENTS
  • TABLE 64: SANOFI'S ANTICIPATED MILESTONES
  • TABLE 65: MAJOR REVENUE GENERATING DRUGS IN BILLION $
  • TABLE 66: PIPELINE DRUGS, IMMUNO - INFLAMMATION AREA
  • TABLE 67: PIPELINE DRUGS, DIABETES AND KIDNEY AREA
  • TABLE 68: PIPELINE DRUGS, CNS AREA
  • TABLE 69: RECENT DRUG FILINGS AND APPROVALS RECEIVED BY MITSUBISHI TANABE PHARMA
  • TABLE 70: RECENT RESEARCH AND DEVELOPMENT ACTIVITIES OF MITSUBISHI TANABE PHARMA
  • TABLE 71: RECENT DEALS ACTIVITIES OF MITSUBISHI TANABE PHARMA
  • TABLE 72: RECENT DEVELOPMENTS OF MITSUBISHI TANABE PHARMA
  • TABLE 73: ADAMAS PIPELINE ASSETS
  • TABLE 74: ADAMAS OWNED PATENTS COVERING GOCOVRI
  • TABLE 75: ADAMAS RESEARCH AND DEVELOPMENT ACTIVITIES
  • TABLE 76: ADAMAS RECENT DEVELOPMENTS
  • TABLE 77: BIOGEN'S PRODUCTS UNDER MULTIPLE SCLEROSIS AND NEUROIMMUNOLOGY
  • TABLE 78: BIOGEN'S PRODUCTS UNDER BIOSIMILARS
  • TABLE 79: BIOGEN'S PRODUCTS UNDER ANTI-CD20
  • TABLE 80: BIOGEN'S PRODUCTS UNDER DEVELOPMENT
  • TABLE 81: BIOGEN'S PATENTS COVERING THEIR PRODUCTS UNDER NEURODEGENERATION
  • TABLE 82: BIOGEN'S RESEARCH AND DEVELOPMENT ACTIVITIES
  • TABLE 83: BIOGEN'S RECENT DEVELOPMENTS
  • TABLE 84: BIOGEN'S ANTICIPATED MILESTONES
  • TABLE 85: NOVARTIS' SALES IN MILLION $ OF TOP 10 PRODUCTS IN 9 MONTHS IN 2019
  • TABLE 86: NOVARTIS' PATENTS COVERING GILENYA
  • TABLE 87: NOVARTIS' IN REGISTRATION MOLECULES
  • TABLE 88: NOVARTIS' PHASE 3 MOLECULES
  • TABLE 89: NOVARTIS' RESEARCH AND DEVELOPMENT ACTIVITIES
  • TABLE 90: NOVARTIS' RECENT DEVELOPMENTS
  • TABLE 91: NOVARTIS' ANTICIPATED MILESTONES
  • TABLE 92: BIOHAVEN'S PIPELINE ASSETS
  • TABLE 93: MAJOR PATENTS PROTECTING RIMEGEPANT AND BHV-3500
  • TABLE 94: RECENT RESEARCH AND DEVELOPMENT ACTIVITIES AND DEVELOPMENTS OF BIOHAVEN
  • TABLE 95: ANTICIPATED NEAR FUTURE MILESTONES OF BIOHAVEN
  • TABLE 96: AXSOME'S PRODUCT PORTFOLIO
  • TABLE 97: AXSOME'S LATEST PATENTS
  • TABLE 98: AXSOME'S RESEARCH AND DEVELOPMENT ACTIVITIES
  • TABLE 99: AXSOME'S RECENT DEVELOPMENTS
  • TABLE 100: AZTHERAPIES PRODUCT PORTFOLIO
  • TABLE 101: AZTHERAPIES LATEST PATENTS
  • TABLE 102: AZTHERAPIES RESEARCH AND DEVELOPMENT ACTIVITIES
  • TABLE 103: AZTHERAPIES RECENT DEVELOPMENTS
  • TABLE 104: BRAINSTORM CELL THERAPEUTICS' PIPELINE ASSETS
  • TABLE 105: KEY INTELLECTUAL PROPERTY PORTFOLIO OF BRAINSTORM CELL THERAPEUTICS
  • TABLE 106: RECENT DEVELOPMENTS AND RESEARCH AND DEVELOPMENT ACTIVITIES OF BRAINSTORM
  • TABLE 107: ANTICIPATED NEAR FUTURE MILESTONES OF BRAINSTORM
  • TABLE 108: MEDICINOVA'S PIPELINE ASSETS
  • TABLE 109: PATENTS COVERING MN-166(IBUDILAST)
  • TABLE 110: PATENTS COVERING MN-001 (TIPELUKAST)
  • TABLE 111: RECENT RESEARCH AND DEVELOPMENT ACTIVITIES AND DEVELOPMENTS OF MEDICINOVA
  • TABLE 112: MAPI'S PIPELINE ASSETS
  • TABLE 113: MAPI'S LATEST GRANTED PATENTS AND PATENT APPLICATIONS
  • TABLE 114: MAPI'S RESEARCH AND DEVELOPMENT ACTIVITIES
  • TABLE 115: MAPI'S RECENT DEVELOPMENTS
  • TABLE 116: TG THERAPEUTICS PRODUCT PIPELINE
  • TABLE 117: TG THERAPEUTICS RESEARCH AND DEVELOPMENT ACTIVITIES
  • TABLE 118: TG THERAPEUTICS RECENT DEVELOPMENTS
  • TABLE 119: AB SCIENCE'S PRODUCT PIPELINE WITH RESPECT TO NEUROSCIENCES
  • TABLE 120: AB SCIENCE'S PRODUCT PIPELINE WITH RESPECT TO MASTOCYTOSIS
  • TABLE 121: AB SCIENCE'S PRODUCT PIPELINE WITH RESPECT TO ASTHMA
  • TABLE 122: AB SCIENCE'S PRODUCT PIPELINE WITH RESPECT TO CANCERS
  • TABLE 123: AB SCIENCE'S PATENT PORFOLIO
  • TABLE 124: AB SCIENCE'S RESEARCH AND DEVELOPMENT ACTIVITIES
  • TABLE 125: AB SCIENCE'S RECENT DEVELOPMENTS
  • TABLE 126: INTEC'S PRODUCT PIPELINE
  • TABLE 127: INTEC'S PATENTS
  • TABLE 128: INTEC'S RESEARCH AND DEVELOPMENT ACTIVITIES
  • TABLE 129: INTEC'S RECENT DEVELOPMENTS
  • TABLE 130: CORTEXYME'S PATENTS AND PATENT APPLICATIONS
  • TABLE 131: CORTEXYME'S RESEARCH AND DEVELOPMENT ACTIVITIES
  • TABLE 132: CORTEXYME'S RECENT DEVELOPMENTS
  • TABLE 133: INTRA-CELLULAR'S PRODUCT PIPELINE WITH RESPECT TO LUMATEPERONE
  • TABLE 134: INTRA-CELLULAR'S PRODUCT PIPELINE WITH EXCLUDING LUMATEPERONE
  • TABLE 135: INTRA-CELLULAR'S RESEARCH AND DEVELOPMENT ACTIVITIES
  • TABLE 136: INTRA-CELLULAR'S RECENT DEVELOPMENTS ACTIVITIES
  • TABLE 137: ANAVEX'S PRODUCT PIPELINE
  • TABLE 138: ANAVEX'S PATENT PORTFOLIO
  • TABLE 139: ANAVEX'S RESEARCH AND DEVELOPMENT ACTIVITIES
  • TABLE 140: ANAVEX'S RECENT AND DEVELOPMENTS
  • TABLE 141: AGENEBIO'S PRODUCT PIPELINE
  • TABLE 142: AGENEBIO'S PATENT PORTFOLIO
  • TABLE 143: AGENEBIO'S RESEARCH AND DEVELOPMENT ACTIVITIES
  • TABLE 144: AGENEBIO'S RECENT DEVELOPMENTS
  • TABLE 145: ALZHEON'S PRODUCT PIPELINE
  • TABLE 146: ALZHEON'S PATENT PORTFOLIO
  • TABLE 147: ALZHEON'S RESEARCH AND DEVELOPMENT ACTIVITIES
  • TABLE 148: ALZHEON'S RECENT DEVELOPMENTS
  • TABLE 149: SOM'S PRODUCT PIPELINE
  • TABLE 150: SOM'S RESEARCH AND DEVELOPMENT ACTIVITIES
  • TABLE 151: SOM'S RECENT DEVELOPMENTS

LIST OF FIGURES

  • FIGURE 01: NEURODEGENERATIVE DISEASES COVERED IN THE REPORT
  • FIGURE 02: ALZHEIMER'S DISEASE EPIDEMIOLOGY FORECAST (US)
  • FIGURE 03: EPIDEMIOLOGY FORECAST PARKINSON'S DISEASE (GLOBAL)
  • FIGURE 04: ALS EPIDEMIOLOGY FORECAST (2019-2025), US
  • FIGURE 05: ALS EPIDEMIOLOGY FORECAST (2019-2025), EUROPE
  • FIGURE 06: NEURODEGENERATIVE DISEASES DEALS BY DEAL TYPE
  • FIGURE 07: NEURODEGENERATIVE DISEASES DEALS FREQUENCY IN 2019
  • FIGURE 08: NEURODEGENERATIVE DISEASE DEALS FREQUENCY IN 2018
  • FIGURE 09: NEURODEGENERATIVE DISEASES DEALS FREQUENCY IN 2017
  • FIGURE 10: NEURODEGENERATIVE DISEASES DEALS FREQUENCY IN 2016
  • FIGURE 11: NEURODEGENERATIVE DISEASES DEALS FREQUENCY IN 2015
  • FIGURE 12: ALZHEIMER'S DISEASE DEALS, BY DEAL TYPE
  • FIGURE 13: PARKINSON'S DISEASE DEALS, BY DEAL TYPE
  • FIGURE 14: AMYOTROPHIC LATERAL SCLEROSIS DEALS, BY DEAL TYPE
  • FUGURE 15: MULTIPLE SCLEROSIS DEALS, BY DEAL TYPE
  • FIGURE 16: HUNTINGTON'S DISEASE DEALS, BY DEAL TYPE
  • FIGURE 17: COMPANIES INVOLVED IN R&D OF DRUGS FOR TOP 5 DISEASES
  • FIGURE 18: TOTAL NUMBER OF DRUG CANDIDATES, HSD SPLIT
  • FIGURE 19: ALZHEIMER'S DISEASE PIPELINE DRUGS WITH RESPECT TO STAGE OF DEVELOPMENT
  • FIGURE 20: PIPELINE ANALYTICS BY GEOGRAPHY
  • FIGURE 21: PIPELINE ANALYTICS BY ROUTE OF ADMINISTRATION
  • FIGURE 22: PAKINSON'S DISEASE PIPELINE DRUGS WITH RESPECT TO STAGE OF DEVELOPMENT
  • FIGURE 23: PIPELINE ANALYTICS BY GEOGRAPHY
  • FIGURE 24: PIPELINE ANALYTICS BY ROUTE OF ADMINISTRATION
  • FIGURE 25: PIPELINE MOLECULES IN AMYOTROPHIC LATERAL SCLEROSIS AREA, PERCENT SHARE
  • FIGURE 26: ALS PIPELINE SPLIT BY GEOGRAPHY, NUMBER OF EXPECTED DRUG APPROVALS
  • FIGURE 27: AMYOTROPHIC LATERAL SCLEROSIS DRUG PIPELINE SPLIT BY GEOGRAPHY
  • FIGURE 28: ORALS BY HSD SPLIT-UP
  • FIGURE 29: INJECTABLES BY HSD SPLIT-UP
  • FIGURE 30: MULTIPLE SCLEROSIS PIPELINE DRUGS WITH RESPECT TO STAGES OF DEVELOPMENT
  • FIGURE 31: DRUG PIPELINE SPLIT BY ROA, MULTIPLE SCLEROSIS
  • FIGURE 32: PIPELINE MOLECULES IN HUNTINGTON'S DISEASE AREA, PERCENT SHARE
  • FIGURE 33: HUNTINGTON'S DISEASE PIPELINE MOLECULES, ROA SPLIT
  • FIGURE 34: PIPELINE MOLECULES IN PSP DRUG PIPELINE
  • FIGURE 35: COMPARISON OF TOP FIVE COMPANIES BASED ON R&D INVESTMENTS IN MILLION $
  • FIGURE 36: PIPELINE PORTFOLIO WITH (NUMBER OF MOLECULES)
  • FIGURE 37: EXPECTED MARKET ENTRY IRRESPECTIVE OF NEURODEGENERATIVE DISEASE AREA
  • FIGURE 38: EXPECTED MARKET ENTRY WITH RESPECT TO NEURODEGENERATIVE DISEASE AREA
  • FIGURE 39: PATENT PORTFOLIO COMPARISON OF TOP 10 EMERGING COMPANIES
  • FIGURE 40: TIME LINE OF PATENT EXPIRIES IRRESPECTIVE OF NEURODEGENERATIVE DISEASE AREA
  • FIGURE 41: TIME LINE OF PATENT EXPIRIES WITH RESPECT TO NEURODEGENERATIVE DISEASE AREA
  • FIGURE 42: RANKING TOP 10 EMERGING COMPANIES BASED ON THEIR PARTNERING ACTIVITIES
  • FIGURE 43: RANKING TOP 10 EMERGING COMPANIES BASED ON THEIR REGULATORY ALLOWANCES
  • FIGURE 44: COMPARISON PIE CHARTS FOR INCOME GAINED THROUGH SALES IN 2018 AND 2019
  • FIGURE 45: MITSUBISHI TANABE PHARMA, ANNUAL SALES V/S R&D EXPENSES IN BILLION DOLLARS
  • FIGURE 46: MITSUBISHI TANABE PHARMA, FY 2018 ANNUAL REVENUE SPLIT BY GEOGRAPHIES
  • FIGURE 47: MITSUBISHI TANABE PHARMA, FY 2018 ANNUAL REVENUE SPLIT
  • FIGURE 48: ADAMAS REVENUES FOR NINE MONTHS COMPLETED IN THOUSAND $ FOR 2018 AND 2019
  • FIGURE 49: ADAMAS OPERATING EXPENSES IN THOUSAND $ FOR 2016, 2017 AND 2018
  • FIGURE 50: ADAMAS RESEARCH AND DEVELOPMENT EXPENSES FOR NINE MONTHS IN 2019
  • FIGURE 51: BIOGEN'S REVENUES ATTAINED FOR FIRST NINE MONTHS IN 2019
  • FIGURE 52: BIOGEN'S OPERATING EXPENSES IN MILLION $ FOR 2016, 2017 AND 2018
  • FIGURE 53: NOVARTIS' BREAKDOWN OF REVENUES EARNED IN THE YEAR END OF 2018
  • FIGURE 54: NOVARTIS' REVENUES EARNED IN MILLION $ FOR 2016, 2017 AND 2018
  • FIGURE 55: TOTAL OPERATIONAL EXPENSES OF BIOHAVEN IN THOUSAND $
  • FIGURE 56: TOTAL RESEARCH AND DEVELOPMENT EXPENSE OF BIOHAVEN IN MILLION $
  • FIGURE 57: AXSOME'S OPERATING EXPENSES FOR FINANCIAL YEARS OF 2016, 2017 AND 2018 IN THOUSAND $
  • FIGURE 58: RESEARCH AND DEVELOPMENT EXPENSE OF BRAINSTORM IN MILLION $ (2017 AND 2018)
  • FIGURE 59: OPERATIONAL COSTS OF BRAINSTORM IN MILLION $ (2017 AND 2018)
  • FIGURE 60: TOTAL R&D EXPENSE OF MEDICINOVA (2016, 2017 AND 2018) IN THOUSAND $
  • FIGURE 61: TOTAL OPERATIONAL EXPENSES OF MEDICINOVA IN THOUSAND $ FOR 2014, 2015, 2016, 2017 AND 2018
  • FIGURE 62: TG THERAPEUTICS R&D EXPENSES FOR FIRST 9 MONTHS IN 2018 AND 2019 IN THOUSAND $
  • FIGURE 63: TG THERAPEUTICS OPERATION EXPENSES FOR 2016, 2017 AND 2018 IN THOUSAND $
  • FIGURE 64: OPERATIONAL EXPENSES FOR YEARS 2017 AND 2018 IN THOUSAND €
  • FIGURE 65: RESEARCH AND DEVELOPMENT FOR FIRST HALF OF 2018 AND 2019 IN THOUSAND €
  • FIGURE 66: RESEARCH AND DEVELOPMENT EXPENSES FOR FIRST NINE MONTHS OF 2018 AND 2019 IN THOUSAND $
  • FIGURE 67: RESEARCH AND DEVELOPMENT EXPENSES FOR YEARS 2017 AND 2018 IN THOUSAND $
  • FIGURE 68: CORTEXYME'S RESEARCH AND DEVELOPMENT EXPENSES FOR 2017 AND 2018 IN THOUSAND $
  • FIGURE 69: CORTEXYME'S R&D EXPENSES FOR FIRST NINE MONTHS OF 2018 AND 2019 IN THOUSAND $
  • FIGURE 70: INTRA-CELLULAR'S R&D EXPNSES FOR FIRST NINE MONTHS OF 2018 AND 2019 IN THOUSAND $
  • FIGURE 71: INTRA-CELLULAR'S OPERATIONAL EXPENSES FOR 2016, 2017 AND 2018 IN THOUSAND $
  • FIGURE 72: ALZHEON'S OPERATING EXPENSES FOR FINANCIAL YEARS OF 2016 AND 2017 IN THOUSAND $
  • FIGURE 73: ALZHEON'S R&D EXPENSES FOR FIRST HALF OF YEARS OF 2016 AND 2017 IN THOUSAND $